Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
Australia’s Corporate Leaders Face Parliament Over KPMG Client Data Scandal 
Lenovo Revenue Surges 43% as AI Demand Drives Record First-Quarter Growth 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
Alphabet’s SpaceX Investment Soars 100-Fold to $94 Billion 
Ford to Move Some Lincoln Production From China to U.S. in 2030 
Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO 
Super Micro Stock Jumps 19% as AI Server Demand Drives Strong 2027 Outlook 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
SMIC Shares Rally as Q2 Profit Surges 262% on Strong Chip Demand 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
Sanrio Shares Plunge as Q1 Profit Miss Overshadows Strong Sales 
Stripe, Advent Reportedly Pursue $53 Billion PayPal Takeover 
Tesla Roadster Reveal Could Feature SpaceX Thrusters in August 
Add as a preferred source on Google
Eisai Co., Ltd., a Japanese pharmaceutical company headquartered in Tokyo, Japan, is set to roll out its novel, Leqembi, developed to treat Alzheimer's disease. The company is expected to give the first doses to 1,500 patients in China on the launch of this new medical product.
Growth Prediction After Leqembi's Release
According to Reuters, Eisai will also experience massive growth once the Leqembi officially hits the market. The new drug for Alzheimer's disease will first be available for Chinese patients later this year.
The pharma company's spokesperson explained that it anticipates growth to speed up even more in 2025 because the disease's diagnosis also changes. Moreover, the representative said that more suitable Alzheimer's blood tests will also be ready, and this will further help the company reach a more significant share of the Chinese market, where an estimated 17 million people were diagnosed with an early stage of Alzheimer's.
"China is one of the fastest-aging countries in the world and is one of the most important countries in the area of Alzheimer's disease for Eisai," Eisai's spokesman stated. "The potential growth for Leqembi in China is huge."
Price and Eligibility
Eisai plans to release Leqembi in China and sell it for 200,000 yuan or around $28,180 annually. The company said it has not yet decided if it will ask for government coverage and will only do so after assessing the demand in the private market. If Eisai pushes through, it will be included on China's National Reimbursement Drug List, and prices could be reduced.
To be eligible for treatment with Eisai's Leqembi, patients must undergo cognitive and genetic testing to determine whether they have a gene that increases the drug's adverse side effects.
They must also go through testing to see if they have abnormal levels of amyloid. Once the treatment begins, all patients will still undergo a series of MRI scans to detect any potential fatal swelling and bleeding in the brain.
Approval of LEQEMBI By the FDA
The FDA approved Eisai's Leqembi in July 2023 to treat Alzheimer's Disease. According to the press release, it is the first and only approved treatment that has been able to lessen the rate of the disease's progression. The drug can also slow down cognitive and functional decline in adult patients.
Photo by: Eisai Website
